Abstract: The present invention relates to an automated driving system for switching between automated driving mode and manual driving mode in an automated driving situation, and a fallback method for an automated driving failure situation in the automated driving system. According to the present invention, the method comprises the steps of predicting whether, on a route a vehicle is traveling, the vehicle will deviate from an operational design domain (ODD) in which automated driving is possible; and when deviation is predicted, performing a minimal risk maneuver (MRM) process for controlling the vehicle to respond to an automated driving failure situation at a deviation point. According to the present invention, the stability of the automated driving system in emergency situations may be increased, and by proposing a stable mode-switching method for the automated driving system, the best response method may be provided.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes, comprising, as active ingredients: (a) a zinc salt, comprising a zinc cation and anion, and cyclo-hispro, or a pharmaceutically acceptable salt thereof; and (b) an antidiabetic drug (particularly, an insulin sensitizer, an insulin sensitizer, a sodium-glucose co-transporter (a sodium-glucose co-transporter 2 (SGLT2) inhibitor), or a DPP-4 inhibitor).

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating obesity, comprising cyclo-hispro as an active ingredient. Specifically, the present invention has the effect of reducing body weight and body mass, and further improving leptin resistance. In addition, the present invention relates to a pharmaceutical composition for preventing or treating obesity, characterized in that the pharmaceutical composition comprises cyclo-hispro and zinc and is administered once a day.

Abstract: The present invention relates to a pharmaceutical formulation for preventing or treating diabetes mellitus, comprising cyclo-hispro as an active ingredient. Specifically, the present invention has the effect of lowering the concentration of glycated hemoglobin (HbA1c) in the blood, and further improving leptin resistance. In addition, the present invention relates to a pharmaceutical formulation for preventing or treating diabetes mellitus, characterized in that the pharmaceutical formulation comprises cyclo-hispro and zinc and is administered once a day.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes, comprising, as active ingredients: (a) a zinc salt, comprising a zinc cation and anion, and cyclo-hispro, or a pharmaceutically acceptable salt thereof; and (b) an antidiabetic drug (particularly, an insulin sensitizer, an insulin sensitizer, a sodium-glucose co-transporter (a sodium-glucose co-transporter 2 (SGLT2) inhibitor), or a DPP-4 inhibitor).

Abstract: The present invention relates to a composition for preventing or treating atherosclerosis in a subject, comprising a zinc salt and cyclo-Hispro and a method of preventing or treating atherosclerosis using thereof.